Skip to main content

Table 3 Cox univariate proportional-hazards analysis for filter clotting during first filter use

From: Continuous renal replacement therapy in COVID-19—associated AKI: adding heparin to citrate to extend filter life—a retrospective cohort study

Risk factor

All patients

p

(N = 238)

HR (95% CI)

Heparin use

0.37 (0.25–0.55)

< 0.001

COVID-19 diagnosis

0.87 (0.55–1.38)

0.561

Age, per year increase

1.01 (1.00–1.03)

0.144

Male sex

1.28 (0.83–1.96)

0.266

D-dimer level,* per 1000 increase

1.01 (1.00–1.02)

0.003

Hemoglobin level

1.12 (1.04–1.21)

0.003

Platelet count, per 100,000 increase

1.00 (1.00–1.00)

0.299

BUN, per 10 increase

1.00 (0.95–1.04)

0.922

ACD-A 4–5 mmol/L vs. 2–3 mmol/L

0.82 (0.54–1.23)

0.331

Vasopressor use

0.93 (0.51–1.70)

0.826

Treatment modality

0.55 (0.27–1.14)

0.109

Obesity

1.09 (0.70–1.69)

0.703

  1. HR, hazard ratio; COVID-19, coronavirus disease 2019, BUN, blood urea nitrogen; ACD-A, anticoagulant citrate dextrose solution formula A
  2. *Value obtained closest to the initiation of renal replacement therapy (median 5990 ng/ml)
Back to article page

Critical Care

ISSN: 1364-8535